Sino Biopharmaceutical Ltd (1177) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Sino Biopharmaceutical Ltd stock HK$6.19, price HK$5.63, upside +10.0%, quality 71 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
The stock costs about what our calculation considers fair.
Quality 71/100
Low debt
Generates free cash flow
2.1% dividend yield · Sustainable
Ranks above peers(11/15)
Fair value HK$6.19 · Fairly valued (+10.0%)
Mixed Growth(revenue 5y +6.1 %/yr in CNY)
Thin margins · 7.1% net margin (TTM)
Moderate moat60/100 · thin data
Negative coverage
Thin data
Quality growth
Risks from the AI analysis
🚩Volume-based procurement squeezing pricing on established products🚩FDA import alert blocks US peptide API sales🚩Sharp rise in total debt raises refinancing risk
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range HK$2.24 – HK$8.91 · fair‑value band HK$4.33 – HK$8.04 · the HK$5.63 price screens below the HK$6.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Sino Biopharmaceutical in your weekly email
Every Wednesday you see whether Sino Biopharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.
Show moreShow less
The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand.
It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin.
In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208.
Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Stock analysis
Sino Biopharmaceutical Ltd (1177) currently trades at HK$5.63, while our model-based Fair Value estimate is HK$6.19, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$5.11 per share, and 4 of the 26 models we run sit above the HK$5.63 price.
Bear case: the Dividend Discount group reads lowest at HK$0.7200, and 22 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$4.33 (bear) to HK$8.04 (bull), the price of HK$5.63 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sino Biopharmaceutical Ltd reported revenue of 31.8B CNY in FY2025 versus 26.9B CNY in FY2021, a compound +4.3%/yr. Reported net income was 2.3B CNY in FY2025, compounding −36.7%/yr from FY2021.
Key figures
Market cap HK$102B (≈ $12.9B) Large · P/E ratio 33.2 · P/S ratio 2.44 · Dividend yield 2.1% · Net margin 7.4% · Return on equity 14.1% · Return on assets (EBIT) 8.9% · Operating margin 34.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, 1177 screens cheaper than that median.
Fair Value models
BearHK$4.33Fair Value HK$6.19BullHK$8.04
Price HK$5.63 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Start year 2020 (pandemic). Over 10 years: +10.1% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−10.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.2%
Dividend (yield on the price)2.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12.2% vs 2.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 22%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −5.8% a year for the price and +5.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (39 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
AI conclusion: The business draws strength from innovative drug and out-licensing revenues now nearing half of sales, yet its main weak point remains thin evidence of a durable moat alongside modest returns on equity.
Main risk: An FDA import alert on a manufacturing subsidiary could bar peptide active pharmaceutical ingredients from the US market and thereby reduce export revenues and margins.
Bull case: By leveraging its growing out-licensing pipeline and AI-enhanced research platforms the company could offset any US market restrictions through stronger partnerships in Europe and Asia while using debt to fund further acquisitions.
Bear case: Persistent regulatory barriers in key export markets combined with elevated debt servicing costs could constrain investment in new therapies and slow the shift toward innovative drugs.
Sino Biopharmaceutical has driven innovative drug and out-licensing revenue up 44 percent in the first half, now accounting for nearly half of total sales. At the same time the company still trails many peers in truly cutting-edge therapies while volume-based procurement continues to squeeze pricing on established products. Will the stream of new approvals and partnerships deliver growth that outpaces those margin pressures?
Compare Sino Biopharmaceutical Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 561 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+10.0% · Top 25%
Profitability
Return on equity (12 months)14.1% · Top 25%
Return on assets7.0% · Top 25%
Net margin (12 months)16.1% · Above median
Operating margin (12 months)34.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)10.6% · Above median
Dividend yield (12 months)2.1% · Above median
Balance sheet
Debt / equity0.25× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sino Biopharmaceutical Ltd (1177) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of HK$6.19 versus a price of HK$5.63, about +10% upside (fairly valued).
What is the fair value of 1177?
Our model-based fair value for Sino Biopharmaceutical Ltd is HK$6.19 (as of Nov 5, 2026), built from audited fundamentals. The current price: HK$5.63.
What is the quality score of 1177?
Sino Biopharmaceutical Ltd has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sino Biopharmaceutical Ltd (1177)?
Our model-based price target is the fair value of HK$6.19 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario HK$4.33, optimistic scenario HK$8.04. It is a calculation from audited fundamentals, not an analyst target.
What is the Sino Biopharmaceutical Ltd stock forecast for 2026?
Our models put fair value at HK$6.19, about +10% upside versus a price of HK$5.63 (fairly valued). Cautious scenario HK$4.33, optimistic scenario HK$8.04. The calculation is refreshed regularly with new filings.
What is the revenue of Sino Biopharmaceutical Ltd (1177)?
Sino Biopharmaceutical Ltd reported trailing-twelve-month revenue of about 33.7B CNY (latest available figure, as of Nov 5, 2026).
Does Sino Biopharmaceutical Ltd pay a dividend?
Sino Biopharmaceutical Ltd currently shows a dividend yield of 2.13% relative to its recent price (as of Nov 5, 2026).
What growth is priced into Sino Biopharmaceutical Ltd (1177)?
For today's price to be fair in a discounted-cash-flow model, Sino Biopharmaceutical Ltd would have to grow free cash flow by -4.2 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 1177 use?
Our models discount Sino Biopharmaceutical Ltd at 8.8 %: a base by market capitalisation (large), damped by beta 0.61, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sino Biopharmaceutical Ltd that is -4.2 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has Sino Biopharmaceutical Ltd (1177) delivered so far?
Over the past 5 years revenue at Sino Biopharmaceutical Ltd grew +6.1 % a year. The price currently implies -4.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sino Biopharmaceutical Ltd (1177) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sino Biopharmaceutical Ltd (-4.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sino Biopharmaceutical Ltd (1177)?
The free-cash-flow yield on the price is 8.79 %: that much free cash flow Sino Biopharmaceutical Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sino Biopharmaceutical Ltd (1177)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sino Biopharmaceutical Ltd it is HK$6.19 per share (as of Nov 5, 2026), against a price of HK$5.63. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sino Biopharmaceutical Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 1177 trades below its calculated fair value: price HK$5.63, fair value HK$6.19, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1177?
No. The price is what the market pays today (HK$5.63); the fair value is what the company's own numbers justify (HK$6.19). For Sino Biopharmaceutical Ltd the two are HK$0.5625 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sino Biopharmaceutical Ltd worth?
The market values Sino Biopharmaceutical Ltd at about HK$102B (market capitalisation, as of Nov 5, 2026). Per share that is HK$5.63; our models calculate a fair value of HK$6.19 per share.
What do the bullish and bearish scenarios say about 1177?
Our models span a range for Sino Biopharmaceutical Ltd: cautious scenario HK$4.33, base HK$6.19, optimistic HK$8.04 per share (as of Nov 5, 2026, price HK$5.63). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1177?
Sino Biopharmaceutical Ltd trades at a price-to-earnings ratio of 33.2 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$6.19 is built from several models across several years. Other multiples: PEG 0.7, P/B 2.8, P/S 5.8, EV/EBITDA 18.8.
What is the PEG ratio of 1177?
The PEG ratio of Sino Biopharmaceutical Ltd is 0.72 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Sino Biopharmaceutical Ltd (1177)?
Balance-sheet figures for Sino Biopharmaceutical Ltd (as of Nov 5, 2026): return on equity 14.1%, debt of 0.25 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is 1177 from its 52-week high?
Sino Biopharmaceutical Ltd trades at HK$5.63, about 23% below its 52-week high of HK$7.29 and 32% above the low of HK$4.26 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.19 is for.
Which stocks are comparable to Sino Biopharmaceutical Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sino Biopharmaceutical Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price HK$5.63, calculated fair value HK$6.19 (+10%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1177 calculated?
We run Sino Biopharmaceutical Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.19, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Sino Biopharmaceutical Ltd currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sino Biopharmaceutical Ltd (1177)?
The closing price on Nov 5, 2026 was HK$5.63. Our model-based fair value is HK$6.19, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sino Biopharmaceutical Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$4.33 to HK$8.04) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Sino Biopharmaceutical Ltd (1177) come from?
Earnings per share at Sino Biopharmaceutical Ltd grew +4.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.8 %, EBIT margin −1.9 %, tax rate −0.5 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sino Biopharmaceutical Ltd
How large is the market capitalisation of Sino Biopharmaceutical Ltd (1177)?
The market capitalisation of Sino Biopharmaceutical Ltd is HK$102B (≈ $12.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sino Biopharmaceutical Ltd (1177)?
The price-to-sales ratio of Sino Biopharmaceutical Ltd is 2.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Sino Biopharmaceutical Ltd (1177)?
The dividend yield of Sino Biopharmaceutical Ltd is 2.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sino Biopharmaceutical Ltd (1177)?
The net margin of Sino Biopharmaceutical Ltd is 7.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sino Biopharmaceutical Ltd (1177)?
The return on equity (ROE) of Sino Biopharmaceutical Ltd is 14.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sino Biopharmaceutical Ltd (1177)?
On an EBIT basis the return on assets of Sino Biopharmaceutical Ltd is 8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sino Biopharmaceutical Ltd (1177)?
The operating margin of Sino Biopharmaceutical Ltd is 34.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sino Biopharmaceutical Ltd (1177)?
Revenue at Sino Biopharmaceutical Ltd is growing +10.6% versus a year earlier (3y avg +6.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sino Biopharmaceutical Ltd (1177)?
Earnings per share at Sino Biopharmaceutical Ltd are growing +1.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sino Biopharmaceutical Ltd (1177) carry?
The net debt of Sino Biopharmaceutical Ltd is 8.7B CNY (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sino Biopharmaceutical Ltd in the live analysis
One click puts Sino Biopharmaceutical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026